Onconetix, Inc is a biotechnology firm, specializes in men's health and oncology solutions.
Onconetix, Inc., headquartered in Cincinnati, Ohio, is a pioneering biotechnology firm dedicated to advancing solutions in men's health and oncology through rigorous research, development, and commercialization efforts. Established in 2018, the company focuses on addressing critical medical needs with innovative products that improve patient outcomes.
At the forefront of Onconetix's offerings is Entadfi, an FDA-approved, once-daily pill that combines finasteride and tadalafil. This medication is specifically designed for the treatment of benign prostatic hyperplasia (BPH), providing patients with a convenient therapeutic option to manage this prevalent condition effectively. Additionally, the company has developed Proclarix, a cutting-edge in vitro protein-based blood diagnostic test tailored for detecting prostate cancer. Proclarix represents a significant advancement in early cancer detection, supporting timely interventions and personalized treatment approaches.
Formerly known as Blue Water Biotech, Inc., Onconetix underwent a name change in December 2023 to reflect its strategic focus on oncology and men's health. With a commitment to innovation and patient-centric solutions, Onconetix continues to expand its portfolio and strengthen its presence in the biotechnology landscape, aiming to redefine standards in disease management and diagnostics.